Yasuyoshi Arikawa

This inventor holds 17 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignees: Takeda Pharmaceutical Company Limited, Takeda Chemical Industries, Inc.. Active years: 2002-2025.

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 88.2

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 43(Granted Patents)

Location History:

Hirakata, JP (2002 - 2008)
Osaka, JP (2012 - 2015)
San Diego, CA (US) (2015)
Fujisawa, JP (2018)
Kanagawa, JP (2015 - 2024)

Company Filing History:

16 out of 1,226

Takeda Pharmaceutical Company Limited

patents

1 out of 1,858

Takeda Chemical Industries, Inc.

patents

Years Active: 2002-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435063 - Nitrogen containing heterocycles as CDK12 inhibitors (2025-10-07),

2. 12084436 - Heterocyclic compound (2024-09-10),

3. 11584737 - Heterocyclic compound (2023-02-21),

4. 11230545 - Heterocyclic compound (2022-01-25),

5. 10435399 - HDAC6 inhibitory heterocyclic compound (2019-10-08),

6. 10131653 - Heterocyclic compound (2018-11-20),

7. 9181255 - Fused heteroaromatic pyrrolidinones as SYK inhibitors (2015-11-10),

8. 9108970 - Fused heteroaromatic pyrrolidinones (2015-08-18),

9. 8993598 - Pyrrole compounds (2015-03-31),

10. 8969387 - Pyrrole compounds (2015-03-03),

11. 8933105 - Pyrrole compounds (2015-01-13),

12. 8592597 - Pyrrole compounds (2013-11-26),

13. 8440689 - Fused heteroaromatic pyrrolidinones (2013-05-14),

14. 8334301 - 5-Membered heterocyclic compound (2012-12-18),

15. 7456162 - Benzofuran derivatives, their production and use (2008-11-25),

Title: Yasuyoshi Arikawa: Innovator in Pharmaceutical Chemistry

Introduction

Yasuyoshi Arikawa is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target critical biological pathways. With a total of 17 patents to his name, Arikawa's work is recognized for its potential impact on cancer treatment and neurodegenerative diseases.

Latest Patents

Among his latest patents, Arikawa has developed nitrogen-containing heterocycles as CDK12 inhibitors. This compound is expected to exhibit superior CDK12 inhibitory action, making it a promising candidate for prophylactic or therapeutic applications in cancer treatment. Additionally, he has introduced a heterocyclic compound with HDAC inhibitory action, which is useful for treating central nervous system diseases, including neurodegenerative disorders. These innovations highlight his commitment to advancing medical science through targeted drug development.

Career Highlights

Throughout his career, Yasuyoshi Arikawa has worked with notable companies, including Takeda Pharmaceutical Company Limited and Takeda Chemical Industries, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Arikawa has collaborated with esteemed colleagues such as Haruyuki Nishida and Masahiro Ito. These partnerships have fostered an environment of innovation and have led to the successful development of several impactful pharmaceutical compounds.

Conclusion

Yasuyoshi Arikawa's contributions to pharmaceutical chemistry are significant and continue to influence the development of new therapeutic agents. His innovative work in creating compounds for cancer and neurodegenerative diseases showcases his dedication to improving human health.